Pancreatic Cancer Research

ResearcherDalian Medical UniversityActive in the last 2 years

Zhen Ning

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2901-2991; OpenAlex author ID A5100532370. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
16
Papers, trials and grants by year

2014: 4 papers · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 10

  1. The TRIB1-PPARγ Axis Regulates Cholesterol Metabolism in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1111/nyas.70224↗
  2. USP10 activates the FAK pathway by stabilizing RIOK3 in pancreatic ductal adenocarcinoma Co-author DOI 10.21203/rs.3.rs-3941004/v1↗
  3. RIOK3 promotes mTORC1 activation by facilitating SLC7A2-mediated arginine uptake in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/aging.204528↗
  4. RIOK3 promotes pancreatic ductal adenocarcinoma cell invasion and metastasis by stabilizing FAK. Co-author DOI 10.1016/j.heliyon.2022.e10116↗
  5. Cancer associated fibroblasts (CAFs) derived exosomes with A promoted liver metastasis of pancreatic cancer by regulating C through transcription factor B Co-author DOI 10.21203/rs.3.rs-1464033/v1↗
  6. [Corrigendum] USP22 promotes the G1/S phase transition by upregulating FoxM1 expression via β‑catenin nuclear localization and is associated with poor prognosi… Co-author DOI 10.3892/ijo.2019.4871↗
  7. USP22 promotes the G1/S phase transition by upregulating FoxM1 expression via β-catenin nuclear localization and is associated with poor prognosis in stage II … Co-author DOI 10.3892/ijo.2014.2531↗
  8. USP22 promotes epithelial-mesenchymal transition via the FAK pathway in pancreatic cancer cells. Co-author DOI 10.3892/or.2014.3354↗
  9. Ubiquitin‑specific protease 22‑induced autophagy is correlated with poor prognosis of pancreatic cancer. First author DOI 10.3892/or.2014.3508↗
  10. Abnormal expression of Nek2 in pancreatic ductal adenocarcinoma: a novel marker for prognosis. Co-author PMID 24966957↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Henan Qin · 4 shared papers, 2022–2026 · strength 0.85
  2. Mengyuan Xu · 3 shared papers, 2022–2026 · strength 0.66
  3. Aman Wang · 7 shared papers, 2014–2023 · strength 0.64
  4. Jiwei Liu · 4 shared papers, 2014–2024 · strength 0.47
  5. A M Wang · 1 shared paper, 2026 · strength 0.30
  6. Rui Sun · 1 shared paper, 2026 · strength 0.30
  7. Haifeng Luo · 2 shared papers, 2014–2022 · strength 0.23
  8. Zhongyu Wang · 3 shared papers, 2014–2019 · strength 0.20
  9. Shuang Li · 1 shared paper, 2024 · strength 0.19
  10. Rui Sun · 1 shared paper, 2024 · strength 0.19
  11. Peiyuan Yin · 1 shared paper, 2024 · strength 0.19
  12. Guang Tan · 1 shared paper, 2022 · strength 0.19
  13. Jian Du · 1 shared paper, 2022 · strength 0.19
  14. Zhongyu Wang · 1 shared paper, 2014 · strength 0.04
  15. Jinxiao Liang · 1 shared paper, 2014 · strength 0.04
  16. Zhongyu Wang · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.